LeMaitre director adds dividend share rights

Q: What insider transactions did LMAT director John James O'Connor report?

John James O'Connor reported five acquisitions of dividend equivalent rights on September 3, 2026, all classified as grants or awards of derivative securities linked to existing equity awards and held directly.

Q: How many dividend equivalent rights did the LMAT director acquire in total?

The filing reports acquisitions of 0.5429, 0.6503, 0.8852, 1.0022, and 1.6637 dividend equivalent rights. Each right is stated to be the economic equivalent of one share of LEMAITRE VASCULAR INC common stock.

Q: What are dividend equivalent rights in the LMAT Form 4 filing?

Dividend equivalent rights are described as rights that accrue on restricted stock unit and performance share unit awards and vest proportionately with those awards. Each right is the economic equivalent of one share of LEMAITRE VASCULAR INC common stock.

Q: Were any LMAT shares sold or disposed of in this Form 4?

No. The transaction summary shows five acquisition transactions of derivative securities and no sales or disposals of LEMAITRE VASCULAR INC common stock or derivatives in this filing.

Q: Are the LMAT dividend equivalent rights tied to specific prior equity grants?

Yes. The rights accrued on restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025, and vest proportionately with those underlying awards.

Q: Was a Rule 10b5-1 trading plan involved in these LMAT insider transactions?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked, and there is no footnote stating that the transactions were executed pursuant to a Rule 10b5-1 trading plan.

LMAT director John James O'Connor received small dividend equivalent right accruals linked to existing equity awards, with no reported sales.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

LEMAITRE VASCULAR INC (LMAT) director John James O'Connor reported five acquisitions of dividend equivalent rights on September 3, 2026. The awards total a small fractional interest in common stock and all are direct derivative holdings tied to previously granted restricted stock unit and performance share unit awards.

According to the footnotes, each dividend equivalent right is the economic equivalent of one share of common stock and accrues on outstanding equity awards, vesting proportionately with those awards. No Rule 10b5-1 trading plan is reported, and no sales or disposals are listed in this filing.

Insider Trade Summary

Grant/Award: 4.7443 shares

Grant/Award 5 txns

Insider O'Connor John James

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights ^F1	0.5429	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F2	0.6503	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F3	0.8852	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F4	1.0022	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F5	1.6637	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 26.0982 contracts (Direct)

Footnotes (5)

F1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Dividend equivalent rights acquired: 0.5429 rights Dividend equivalent rights acquired: 0.6503 rights Dividend equivalent rights acquired: 0.8852 rights +2 more

5 metrics

Dividend equivalent rights acquired 0.5429 rights Grant/award acquisition on September 3, 2026; economic equivalent of common stock

Dividend equivalent rights acquired 0.6503 rights Grant/award acquisition on September 3, 2026; tied to a performance share unit award

Dividend equivalent rights acquired 0.8852 rights Grant/award acquisition on September 3, 2026; accrues on a 12/6/2024 RSU award

Dividend equivalent rights acquired 1.0022 rights Grant/award acquisition on September 3, 2026; accrues on a 12/6/2024 PSU award

Dividend equivalent rights acquired 1.6637 rights Grant/award acquisition on September 3, 2026; accrues on a 12/10/2025 RSU award

Key Terms

Dividend equivalent rights, restricted stock unit award, performance share unit award, economic equivalent

4 terms

Dividend equivalent rights financial

"These dividend equivalent rights accrued on a restricted stock unit award granted"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"These dividend equivalent rights accrued on a restricted stock unit award granted"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

economic equivalent financial

"Each dividend equivalent right is the economic equivalent of one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did LMAT director John James O'Connor report?

John James O'Connor reported five acquisitions of dividend equivalent rights on September 3, 2026, all classified as grants or awards of derivative securities linked to existing equity awards and held directly.

How many dividend equivalent rights did the LMAT director acquire in total?

The filing reports acquisitions of 0.5429, 0.6503, 0.8852, 1.0022, and 1.6637 dividend equivalent rights. Each right is stated to be the economic equivalent of one share of LEMAITRE VASCULAR INC common stock.

What are dividend equivalent rights in the LMAT Form 4 filing?

Dividend equivalent rights are described as rights that accrue on restricted stock unit and performance share unit awards and vest proportionately with those awards. Each right is the economic equivalent of one share of LEMAITRE VASCULAR INC common stock.

Were any LMAT shares sold or disposed of in this Form 4?

No. The transaction summary shows five acquisition transactions of derivative securities and no sales or disposals of LEMAITRE VASCULAR INC common stock or derivatives in this filing.

Are the LMAT dividend equivalent rights tied to specific prior equity grants?

Yes. The rights accrued on restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025, and vest proportionately with those underlying awards.

Was a Rule 10b5-1 trading plan involved in these LMAT insider transactions?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked, and there is no footnote stating that the transactions were executed pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/08/2026 - 04:47 PM Accepted by SEC EDGAR 09/08/2026 - 04:47 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor John James

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Dividend Equivalent Rights	⁽¹⁾	09/03/2026		A		0.5429		⁽¹⁾	⁽¹⁾	Common Stock	0.5429	$0	5.6103	D
Dividend Equivalent Rights	⁽²⁾	09/03/2026		A		0.6503		⁽²⁾	⁽²⁾	Common Stock	0.6503	$0	5.5195	D
Dividend Equivalent Rights	⁽³⁾	09/03/2026		A		0.8852		⁽³⁾	⁽³⁾	Common Stock	0.8852	$0	5.1836	D
Dividend Equivalent Rights	⁽⁴⁾	09/03/2026		A		1.0022		⁽⁴⁾	⁽⁴⁾	Common Stock	1.0022	$0	5.486	D
Dividend Equivalent Rights	⁽⁵⁾	09/03/2026		A		1.6637		⁽⁵⁾	⁽⁵⁾	Common Stock	1.6637	$0	4.2988	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Douglas G. Bush, Attorney-in-fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

LeMaitre director adds dividend share rights

Rhea-AI Filing Summary

Positive

Negative